Review
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Feb 26, 2024; 16(2): 89-101
Published online Feb 26, 2024. doi: 10.4252/wjsc.v16.i2.89
Unlocking the versatile potential: Adipose-derived mesenchymal stem cells in ocular surface reconstruction and oculoplastics
Pier Luigi Surico, Anna Scarabosio, Giovanni Miotti, Martina Grando, Carlo Salati, Pier Camillo Parodi, Leopoldo Spadea, Marco Zeppieri
Pier Luigi Surico, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, MA 02114, United States
Pier Luigi Surico, Department of Ophthalmology, Campus Bio-Medico University, Rome 00128, Italy
Anna Scarabosio, Giovanni Miotti, Pier Camillo Parodi, Department of Plastic Surgery, University Hospital of Udine, Udine 33100, Italy
Martina Grando, Department of Internal Medicine, Azienda Sanitaria Friuli Occidentale, San Vito al Tagliamento 33078, Italy
Carlo Salati, Marco Zeppieri, Department of Ophthalmology, University Hospital of Udine, Udine 33100, Italy
Leopoldo Spadea, Eye Clinic, Policlinico Umberto I, “Sapienza” University of Rome, Rome 00142, Italy
Co-first authors: Pier Luigi Surico and Anna Scarabosio.
Author contributions: Surico PL and Scarabosio A contributed equally to the manuscript as co-first authors. Surico PL, Scarabosio A, Miotti G, Grando M, Salati C, Parodi PC, Spadea L, and Zeppieri M wrote the outline; Surico PL and Scarabosio A did the research and writing of the manuscript; Miotti G, Grando M, Salati C, Parodi PC, Spadea L, and Zeppieri M assisted in the writing of the paper; Zeppieri M was responsible for the conception and design of the study and completed the English and scientific editing (a native English speaking MD, PhD); Surico PL, Scarabosio A, Miotti G, Grando M, Salati C, Parodi PC, Spadea L, and Zeppieri M assisted in the editing and making critical revisions of the manuscript; and all authors provided the final approval of the article.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Marco Zeppieri, MD, PhD, Doctor, Department of Ophthalmology, University Hospital of Udine, p.le S. Maria della Misericordia 15, Udine 33100, Italy. markzeppieri@hotmail.com
Received: December 7, 2023
Peer-review started: December 7, 2023
First decision: December 31, 2023
Revised: January 6, 2024
Accepted: January 29, 2024
Article in press: January 29, 2024
Published online: February 26, 2024
Processing time: 80 Days and 16.2 Hours
Core Tip

Core Tip: Mesenchymal stem cells (MSCs) have shown great therapeutic potential in all fields of medicine. Adipose-derived MSCs are advantageous, abundant, and relatively safe when considered in treatment regimes. Ophthalmic and oculoplastic surgery that involve procedures for periocular enhancement can benefit from this treatment option for tissue restoration, functional and aesthetic refinement and aging. Adipose-derived MSCs offer immunomodulatory, regenerative, and healing, thus addressing common unmet needs in the field of reconstructive and regenerative surgery. Patient outcomes, success of therapy, prevention of complications and management of patients depend on proper surgical option for individualized tailored needs.